Trinh BQ, Ummarino S, Zhang Y, et al. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021;138(15):1331-1344.

In the author information on page 1331, there are errors in the affiliations of authors Pier Paolo Pandolfi and Daniel G. Tenen. In addition, in the online version of the article, affiliations 14 and 15 in the list below are absent. The author and affiliation lines should appear as shown below.

Bon Q. Trinh,¹ Simone Ummarino,¹ Yanzhou Zhang,¹ Alexander K. Ebralidze,¹ Mahmoud A. Bassal,^2,3 Tuan M. Nguyen,^1,4 Gerwin Heller,⁵ Rory Coffey,¹ Danielle E. Tenen,⁶ Emiel van der Kouwe,⁷ Emiliano Fabiani,^8,9 Carmelo Gurnari,⁸ Chan-Shuo Wu,³ Vladimir Espinosa Angarica,³ Henry Yang,³ Sisi Chen,¹ Hong Zhang,¹ Abby R. Thurm,^2,10 Francisco Marchi,^2,11 Elena Levantini,^1,2,12 Philipp B. Staber,⁷ Pu Zhang,¹ Maria Teresa Voso,⁸ Pier Paolo Pandolfi,^13-15 Susumu S. Kobayashi,^1,2,16 Li Chai,^2,17 Annalisa Di Ruscio,^1,18,19 and Daniel G. Tenen^1-3

¹Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA; ²Harvard Stem Cell Institute, Harvard University, Boston, MA; ³Cancer Science Institute of Singapore, National University of Singapore, Singapore; ⁴Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA; ⁵Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; ⁶Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; ⁷Division of Hematology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; ⁸Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; ⁹Saint Camillus International University of Health Sciences, Rome, Italy; ¹⁰Stanford University School of Medicine, Stanford, CA; ¹¹University of Florida, Gainesville, FL; ¹²Institute of Biomedical Technologies, National Research Council (CNR), Area della Ricerca di Pisa, Pisa, Italy; ¹³Department of Pathology, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA; ¹⁴Molecular Biotechnology Center (MBC), Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy; ¹⁵Renown Institute for Cancer, Nevada System of Higher Education, Reno, NV; ¹⁶Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan; ¹⁷Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ¹⁸Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA; and ¹⁹Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy